Artificial liver device shows promise in early safety trial

NCT ID NCT06285253

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times

Summary

This early-stage study tested a device called miroliverELAP in 10 adults with sudden liver failure. The device acts like an external liver, filtering blood for up to 48 hours to give the liver time to heal or to bridge patients to a transplant. The main goal was to check safety and survival during treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ALCOHOLIC HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Intermountain Healthcare

    Salt Lake City, Utah, 84103, United States

  • Mayo Clinic

    Rochester, Minnesota, 55902, United States

  • Mount Sinai Recanati/Miller Transplantation Institute

    New York, New York, 10029, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • University of Michigan Medical School

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota Medical School

    Minneapolis, Minnesota, 55455, United States

  • Virginia Commonwealth University Medical Center

    Richmond, Virginia, 23970, United States

Conditions

Explore the condition pages connected to this study.